Spruce Biosciences Announces Acceptance Of Abstract For Presentation At The Annual Meeting Of The Endocrine Society
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences (NASDAQ:SPRB) has announced that an abstract on the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH) has been accepted for presentation at the 105th Annual Meeting of the Endocrine Society (ENDO 2023) in Chicago.
June 12, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences' abstract acceptance for ENDO 2023 presentation may increase visibility and interest in the company's novel therapy for rare endocrine disorders.
The acceptance of Spruce Biosciences' abstract for presentation at a prestigious conference like ENDO 2023 indicates that the company's research is being recognized by the scientific community. This could lead to increased visibility and interest in the company's novel therapy for rare endocrine disorders, potentially having a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100